2 completed, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow Respimat: new trials by email Literature Review of Respimat trials Research Report on Respimat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olodaterol Bridging Study in Asthma Respimat, Olodaterol, Olodaterol & BI54903 - Asthma | Phase 2 | Withdrawn | Boehringer Ingelheim | 2011-10-01 | 2011-11-22 | |
| Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD) olodaterol (BI 1744) low, low tiotropium bromide, olodaterol (BI 1744) high - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Boehringer Ingelheim | 233 | 2010-01-01 | 2015-07-15 |
| Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) Tiotropium 0.625 mcg/puff, Tiotropium 1.25 mcg/puff, Tiotropium 2.5 mcg/puff - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Boehringer Ingelheim | 202 | 1998-03-01 | 2025-01-31 |
Pulmonary Disease, Chronic Obstructive (2) · Asthma (1)
Canada (1) · France (1) · Germany (1) · Netherlands (1) · Sweden (1)
2009 (1)